Presentation, Management and Follow-Up of Schilder’s Disease

Garell, P. Charles; Menezes, Arnold H.; Baumbach, Gary L.; Moore, Steven A.; Nelson, Gregg; Mathews, Katherine D.; Afifi, Adel K.

doi:10.1159/000028695

Cited by 21 publications

(15 citation statements)

References 4 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these there are the progressive forms of MS [96], and other diseases close to MS, such as neuromyelitis optica (NMO) or Devic disease [97], Marbur [98] or Schilder disease [99]. A biomarker would ideally be of major importance if able to differentiate these different diseases and anticipate their faster clinical evolution.…”

Section: Biomarkers In the Different Clinical Forms Of Msmentioning

confidence: 99%

Toward biomarkers in multiple sclerosis: new advances

Lolli

Rovero

Chelli

et al. 2006

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Multiple sclerosis is an autoimmune disease that commonly affects young adults. If initially characterized by acute relapses, it is later followed by only incomplete remission. Over years, progressive disability and irreversible deficit lead to chronic neurological deficits in the majority of patients. The clinical course is protracted and unpredictable, and no biological marker is useful in predicting the evolution of autoaggression and disability. It is difficult to diagnose and to monitor disease progression after the initial symptoms or even during the major clinical manifestations, and it is difficult to treat. In this review, the authors report recent advances in the field, focusing on the search of new antigens as a marker of the disease, in their relevance to the pathophysiology and diagnosis of the disease.

show abstract

Section: Biomarkers In the Different Clinical Forms Of Msmentioning

confidence: 99%

Toward biomarkers in multiple sclerosis: new advances

Lolli

Rovero

Chelli

et al. 2006

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…This treatment results in some improvement in the majority of patients. Immunoglobulins have been used with questionable effects in one case and without effect in two patients [60, 62]. …”

Section: Schilder’s Diseasementioning

confidence: 99%

“…Other drugs used were Cyclophosphamide followed by Azathioprine in a 12-year old boy, reported to be stable on this regime, whereas Azathioprine did not prevent the progressive decline in a 12 year old girl [62]. …”

Section: Schilder’s Diseasementioning

confidence: 99%

Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update

Spalice

Parisi²,

Papetti³

et al. 2010

View full text Add to dashboard Cite

Inflammatory demyelinating diseases comprise a spectrum of disorders affecting the myelin of the central and peripheral nervous system. These diseases can usually be differentiated on the basis of clinical, radiological, laboratory and pathological findings. Recent studies have contributed to current awareness that inflammatory demyelinating diseases are not restricted to the adult age group, but are more common in pediatric age than previously believed. Some of pediatric inflammatory demyelinating diseases carry an unfavorable long-term prognosis but appropriate treatments can improve the outcome. The possibility of physical and cognitive disability resulting from these diseases, highlights the urgent need for therapeutic strategies for neurorehabilitation, neuroregeneration, and neurorepair. This review discusses characteristics of primary demyelinating diseases more frequently observed in childhood, focusing on epidemiology, clinical aspects and treatments.

show abstract

“…2,5 In 1925, Flatau published a paper on encephalitis periaxialis (encephileucopathia scleroticans progressiva), now called diffuse myelinoclastic sclerosis or Schilder's Disease, a rare and fatal demyelinating condition that predominately affects children. 2,5,13 On 7 June 1932, at the age of 63, Flatau died from a brain tumour postulated to be glioblastoma multiforme. He diagnosed the affliction himself and kept it secret until his movements became compromised.…”

Section: Introductionmentioning

confidence: 99%

Edward Flatau (1868–1932), Samual Goldflam (1852–1932) and Józef Babinski (1857–1932): Polish pioneers in neurology

Gutowski

2014

J Med Biogr

View full text Add to dashboard Cite

Flatau, Goldflam and Babinski originated from the Russian area of partitioned Poland in the 19th century and knew each other. Each contributed significantly to neurology at a time of adversity in Polish academic life because of the political situation. This paper in the main is centred on Flatau and Goldflam; Babinski, the most recognised of the three, is included for comparison. They all died in 1932, when Poland had been an independent sovereignty since the end of the First World War in 1918.

show abstract

Presentation, Management and Follow-Up of Schilder’s Disease

Cited by 21 publications

References 4 publications

Toward biomarkers in multiple sclerosis: new advances

Toward biomarkers in multiple sclerosis: new advances

Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update

Edward Flatau (1868–1932), Samual Goldflam (1852–1932) and Józef Babinski (1857–1932): Polish pioneers in neurology

Contact Info

Product

Resources

About